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of a Shortage of Bone
Marrow Filters
Many drugs and devices are essential to conduct
hematopoietic stem cell transplantation (HSCT).
The hematopoietic transplant community has been
influenced by numerous drug and device shortages
over the past several years in both Japan and other
countries. This problem has included critical drugs
for hematopoietic transplantations such as gancycrlo-
vir, dexamethasone, lenograstim, imipenam, and ce-
phepime. Recently, the discontinuation in the supply
of the anticancer drug thio-tepa was announced by
a pharmaceutical company in Japan; however, this pro-
cess and decision were not sufficiently disclosed by the
Ministry of Health, Labor, and Welfare (MHLW). As
a result, the hematopoietic transplant communities are
thus considered to urgently require the establishment
of effective management in the event of such future cri-
ses. Although information disclosure is a key to crisis
management, how to disclose bad news to patients re-
mains a difficult issue [1-3] because proactive informa-
tion disclosure may unnecessarily stir up the anxiety ofthe patients. The number of studies focusing on this
topic in the medical field is limited [4].
In December 2008, a termination of the supply of
the Bone Marrow Collection Kit (BMCK) made by
Baxter Limited (Tokyo, Japan) was identified in Japan.
This kit is used for filtering bone marrow(BM) aspirate
during BM transplantations (BMT) [5], and it is essen-
tial for the prevention of thrombosis associated with
the infusion of BM aspirate. As an alternative, the
Bone Marrow Correction System made by the venture
company BioAccess Inc. (Baltimore, MD) is available,
but this product had not been approved in Japan, al-
though it has been approved by the U.S. Food and
Drug Administration (FDA). In Japan, peripheral
blood stem cell transplantations (PBSCs) from unre-
lated donors are not approved, thus resulting in a reli-
ance on BM only, so there was a possibility that the
disruption in the supply of the BM filters would result
in a complete suspension of HSCT from unrelated do-
nors. Considering the stock quantity within Japan (ap-
proximately 500 units) held by Baxter at the end of
December, it was predicted that BMT would not be
available until mid-March 2009.
This problem was eventually resolved by the
prompt approval of the kit from BioAccess by
MHLW on February 26, 2009. However, during this
period, the problem of the disruption in the supply of
the BM filters was widely reported throughout the me-
dia in Japan, thereby generating great public interest.
This case shows the unfavorable impact onmedical
practice if the government does not proactively dis-
close information to society. The responses of
MHLW were slow, and no information was disclosed
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tially revealed; it was only on January 23 that the
MHLW indicated that it would promptly approve
the BioAccess product and pay for it with public health
insurance. This is in contrast to other organizations,
such as the Japan Society for Hematopoietic Cell
Transplantation (JSHCT), the Japan Marrow Donor
Program (JMDP), and the Japan Marrow Donor Reg-
istry Promotion Conference, that responded quickly
after the problem was revealed. Compared to 2008,
the number of BMT from unrelated donors in Febru-
ary 2009 decreased dramatically before increasing
again inMarch (Figure 1). Because each donor collects
and keeps autologous blood, the schedule for bone
marrow harvesting must be determined at least 1
month in advance, and usually 2 months in advance,
before the date of BM harvest. Most BM transplanta-
tions in January 2009 had already been scheduled at
the end of the December 2008, and those could all
be successfully performed due to a sufficient stock of
BMCK. On the other hand, the decrease in the num-
ber of BMT that occurred in 2009 February strongly
indicates a clear association with the shortage of
BMT filters reported at the end of December. The de-
layed information disclosure might havd caused anxi-
ety among patients and healthcare professionals,
resulting in a decreased number of BMT , and it is
highly likely that some patients were unable to receive
BMT at the appropriate time.
This case is thought-provoking, considering the
role that academics can play in a ‘‘critical situation’’
such as that of a sudden termination of the supply of
a medical product. The JSHCT provided information
to healthcare professionals immediately after the
shortage problem was revealed. In addition, they
approached MHLW to solve the problem at an early
point and made the process public. It was probably
effective for the sharing of information among health-
care professionals. The JSHCT introduced a signature
campaign of a patient organization on their Website
and supported the signature campaign. It would be
highly appreciated if increased cooperation between
the community and patients could solve this product
shortage problem. It also probably played an active
role in public policy making.We should therefore rec-
ognize that the establishment of mutual trust between
the transplantation community and society as a whole
is therefore considered to be essential for the further
development of transplantation.
This product shortage problem was caused by the
economic crisis to medical practice. Similar cases will
be possibly repeated in the future. This incident
made a significant political impact. It was repeatedly
reported in the mass media, thereby arousing great
interest of many citizens. The Japanese Diet is now
planning to establish an alternative backup system
for critical drugs or medical devices in the near future.In conclusion, the best method for eliminating anx-
iety among health care professionals and patients is
a thorough disclosure of information, and strong appeal
for the need to establish an appropriate method for in-
formation disclosure. The results of this study may not
be generalized outside of Japan because of the unique
situation in Japan; however, the globalization of the
manufacturing processes could account for sudden cat-
astrophic shortages, as well as the loss ofmanufacturing
credentialing in 1 country that could thus suddenly af-
fect the worldwide supply of critical drugs and medical
goods. We therefore believe that this study would be
beneficial for the optimization of information distribu-
tion in critical situations in many countries.ACKNOWLEDGMENT
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